A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma.
This research is a study looking into a new treatment for people with a type of brain tumour called glioblastoma, which has been newly diagnosed. The new treatment involves a special antibody called L19TNF, which is designed to target tumours. This antibody is being tested alongside a standard chemotherapy drug called temozolomide. The main goals of the study are to understand if this new combination treatment is safe and if it can help patients live longer (survival) and prevent their cancer from growing for a longer time. Researchers will also be checking for side effects and how the body handles the new medication. This study is taking place in different stages.
At a glance
What is this study about?
This study is looking for better ways to treat a serious type of brain cancer called glioblastoma, which has recently been diagnosed. Glioblastoma is a fast-growing tumour in the brain. At the moment, treatments often include surgery, radiotherapy (using radiation to kill cancer cells), and chemotherapy (using drugs). This study is trying out a new type of treatment that adds a special antibody called L19TNF to the usual chemotherapy drug, temozolomide.
Think of L19TNF as a smart missile that's designed to find and attack cancer cells. By combining it with temozolomide, researchers hope to create a more powerful treatment that can control the cancer more effectively than the standard treatment alone. The study is divided into different stages (Phase I and Phase II) which helps researchers carefully check the safety of the new treatment first, and then explore how well it works.
The main aim for the first part of the study is to make sure the treatment is safe and to find the right amount (dose) of the new medication. For the later parts, the researchers will be looking at important things like how long people live after starting the treatment and whether the cancer grows or shrinks. They will also keep a close eye on any side effects and how people feel throughout the study. This research is important because it could lead to new and improved ways of treating glioblastoma, offering more options for patients.
Key takeaways
- The study is for newly diagnosed glioblastoma.
- It tests a new antibody (L19TNF) with standard chemotherapy.
- The main goals are to check safety and how well it works.
- Participants will have regular medical check-ups and scans.
- This research aims to find better glioblastoma treatments.
Who may be eligible?
To join this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
Crucially, you must have been recently diagnosed with glioblastoma, a specific type of brain tumour. The study is for people who are just starting treatment for this condition.
While the basic requirements are straightforward, there will be other specific medical checks to make sure the study treatment is suitable and safe for you. These checks will be done by the study doctors after you express interest.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you recently been diagnosed with glioblastoma?
- Are you generally well enough to start a new treatment?
- Are you able to attend regular hospital appointments?
What does participation involve?
Taking part in this study would involve regular visits to the hospital for checks and treatments. You would receive the study's new antibody treatment (L19TNF) in combination with the standard chemotherapy drug, temozolomide, which is given in capsule form. Doctors and nurses would closely monitor your health, looking for any side effects and seeing how your body is reacting to the medicines. This would involve blood tests, scans (like MRI scans of your brain), and discussions about how you're feeling. The exact number of visits, tests, and the total length of your participation would be explained in detail by the study team, as it can vary depending on which stage of the trial you are in and your individual response to treatment. There would also be follow-up appointments after the main treatment period to continue monitoring your health.
Potential risks and benefits
Locations (2)
- —UnverifiedGermany
- —UnverifiedItaly
Common questions
What is glioblastoma?
Glioblastoma is a serious and fast-growing type of cancer that starts in the brain.
What is L19TNF?
L19TNF is a new type of antibody treatment designed to target and attack cancer cells in the tumour.
What is temozolomide?
Temozolomide is a standard chemotherapy drug often used to treat glioblastoma.
What does 'Phase I' or 'Phase II' mean?
In simply terms, Phase I checks if the treatment is safe, and Phase II checks if it works and what side effects it has.
Will I know if I'm getting the new treatment?
The study team will explain exactly which treatments you would receive and how they are given. It's not usually a comparison between the new treatment vs placebo in this type of study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.